samedan logo
 
 
 
spacer
home > ebr > autumn 2002 > to clone or not to clone: is politics preventing progress?
PUBLICATIONS
European Biopharmaceutical Review

To Clone or Not to Clone: Is Politics Preventing Progress?

Although US President George W. Bush has made it very clear to the American public that he favours a total ban on human cloning - whether for research or for reproductive purposes - legislation to do so has yet to pass muster in the US Senate. The subject of human cloning and stem cell research is being hotly debated in the US while scientists in other countries, unhampered by the prospect of a governmental ban, are forging ahead. Opponents to cloning fear the ethical and moral implications while proponents are keen to find the scientific answers that may one day lead to cures for Alzheimer's, Parkinson's, juvenile diabetes and a number of other debilitating diseases. Will we run amuck with this intensely powerful technology or learn to use it to our best advantage?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By G. Steven Burrill, CEO of Burrill & Company

G. Steven Burrill is CEO of Burrill & Company, a San Francisco-based life sciences merchant bank. Mr Burrill currently serves on eight Boards of Directors including DepoMed (Amex: DMI) and Third Wave Technologies (NASDAQ: TWTI), and is Chairman of the Boards of Pyxis Genomics and Paradigm Genetics (NASDAQ: PDGM).
Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and co-ordinating the firm's services to clients in the biotechnology, life sciences, high technology and manufacturing industries worldwide.

spacer
G. Steven Burrill
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioNet and Sartorius’ company BIA Separations collaborate on production process development of mRNA vaccines

Ajdovšcina, Slovenia & Bangkok, Thailand, 02 November 2021: BioNet, a leading biotech company manufacturing genetically engineered vaccines, and BIA Separations, now part of Sartorius, a leading biochromatography development and manufacturing company, today announced the successful development of an optimized mRNA manufacturing process.
More info >>

White Papers

Considerations for Choosing the Right Wearable Drug Delivery System

West Pharmaceutical Services, Inc.

For patients with chronic conditions, the use of injectable biologic therapies is on the rise. Biologics, while providing considerable therapeutic benefit, can also present several challenges for both drug manufacturers and patients. In particular, many biologics are highly viscous and others require large doses to be injected slowly over time. This can make it difficult to deliver a consistent dose every time, potentially impacting medication adherence.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement